Download PDF
Thromb Haemost 1983; 50(03): 703-706
DOI: 10.1055/s-0038-1665291
Original Article
Schattauer GmbH Stuttgart

The Effect of a Thromboxane Synthetase Inhibitor, Dazoxiben, and Acetylsalicylic Acid on Platelet Function and Prostaglandin Metabolism

Jon Dale
The Medical Department B, Research Institute for Internal Medicine, Rikshospitalet, Oslo, Norway, and Pfizer Central Research, Pfizer Ltd., Sandwich, Kent, England
,
Erik Thaulow
The Medical Department B, Research Institute for Internal Medicine, Rikshospitalet, Oslo, Norway, and Pfizer Central Research, Pfizer Ltd., Sandwich, Kent, England
,
Erik Myhre
The Medical Department B, Research Institute for Internal Medicine, Rikshospitalet, Oslo, Norway, and Pfizer Central Research, Pfizer Ltd., Sandwich, Kent, England
,
John Parry
The Medical Department B, Research Institute for Internal Medicine, Rikshospitalet, Oslo, Norway, and Pfizer Central Research, Pfizer Ltd., Sandwich, Kent, England
› Author Affiliations
Further Information

Publication History

Received 03 December 1982

Accepted 27 July 1983

Publication Date:
18 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Twenty-four men received either placebo, 0.1 g of the thromboxane synthetase inhibitor dazoxiben, 0.25 or 1.0 g of acetylsalicylic acid (ASA). Dazoxiben reduced the maximal rate of collagen-induced platelet aggregation, but less than did ASA. ASA abolished secondary, ADP-induced aggregation, dazoxiben not. Both drugs prolonged the bleeding-time.

Plasma thromboxane B2 (TxB2) levels did not change significantly after dazoxiben, whereas the prostacyclin metabolite 6-keto-PGF1α rose. The larger dose of ASA reduced both TxB2 and 6-keto-PGF1α in plasma. Whole blood was allowed to clot in order to estimate prostaglandin metabolism. Both drugs prevented thromboxane production effectively. Formation of 6-keto-PGF1α decreased by 95 per cent after ASA but was more than doubled after dazoxiben.

Dazoxiben is a selective and effective thromboxane synthetase inhibitor, but has a weaker effect on platelet reactivity than ASA, possibly because endoperoxide formation is not prevented.

Keywords

Thromboxane synthetase inhibition - Cyclo-oxygenase inhibition - Thromboxane - Prostacyclin - Platelet function
 

  • References

  • 1 Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169-2180
    CrossrefPubMedGoogle Scholar
  • 2 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Nat Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 3 Needleman P, Raz A, Ferrendelli JA, Minkes M. Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Nat Acad Sci USA 1977; 74: 1716-1720
    CrossrefPubMedGoogle Scholar
  • 4 Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976; 261: 558-560
    CrossrefPubMedGoogle Scholar
  • 5 Moncada S, Gryglewski RJ, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665
    CrossrefPubMedGoogle Scholar
  • 6 Gorman RR, Bunting S, Miller OV. Modulation of human platelet adenylate cyclase by prostaglandin (PGX). Prostaglandins 1977; 13: 377-388
    CrossrefPubMedGoogle Scholar
  • 7 Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389-397
    CrossrefPubMedGoogle Scholar
  • 8 Fry WL, Czervionke RL, Hoak JC, Smith JB, Haycraft DL. Platelet adherence to cultured vascula cells: Influence of prostacyclin (PGI2). Blood 1980; 55: 271-275
    PubMedGoogle Scholar
  • 9 Szczeklik J, Szczeklik A, Nizankowski R. Haemodynamic changes induced by prostacyclin in man. Br Heart J 1980; 44: 254-258
    CrossrefPubMedGoogle Scholar
  • 10 Wong PY-K, Sun FF, McGiff JC. Metabolism of prostacyclin in blood vessels. J Biol Chem 1978; 253: 5555-5557
    PubMedGoogle Scholar
  • 11 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-235
    CrossrefPubMedGoogle Scholar
  • 12 Rome LH, Lands WE M, Roth GJ, Majerus PW. Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. Prostaglandins 1976; 11: 23-29
    CrossrefPubMedGoogle Scholar
  • 13 Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP. UK-37,248, a novel selective thromboxane synthetase inhibitor with anti-aggregatory and anti-thrombotic activity. Thromb Haemostas 1981; 46: 278 (Abstr)
    PubMedGoogle Scholar
  • 14 Hellem AJ. Platelet adhesiveness in von Willebrand’s disease. A study with a new modification of the glass-bead filter method Scand J Haematol 1970; 7: 374-382
    PubMedGoogle Scholar
  • 15 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
    CrossrefPubMedGoogle Scholar
  • 16 Borchgrevink CF, Waaler B. The secondary bleeding-time. A new method for the differentiation of hemorrhagic diseases Acta Med Scand 1958; 162: 361-374
    CrossrefPubMedGoogle Scholar
  • 17 Tyler HM, Saxton CA P D, Parry MJ. Administration to man of UK- 37,248-01, a selective inhibitor of thromboxane synthetase. Lancet 1981; 1: 629-632
    PubMedGoogle Scholar
  • 18 Vermylen J, Carreras LO, van Schaeren J, Defreyn G, Machin SJ, Verstraete M. Thromboxane synthetase inhibition as anti-thrombotic strategy. Lancet 1981; 1: 1073-1075
    PubMedGoogle Scholar
  • 19 Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium Thromb Res 1977; 11: 323-344
    CrossrefPubMedGoogle Scholar
  • 20 Blackwell GJ, Flower RJ, Russell-Smith N, Salmon JA, Thorogood PB, Vane JR. Prostacyclin is produced in whole blood. Br J Pharmacol 1978; 64: 436
    PubMedGoogle Scholar
  • 21 Defreyn G, Machin SJ, Carreras LO, Vergara DaudenM, Chamone DA F, Vermylen J. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: Reorientation of cyclic endoperoxide metabolism. Br J Haematol 1981; 49: 29-41
    CrossrefPubMedGoogle Scholar
  • 22 Baenziger NL, Becherer PR, Majerus PW. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell 1979; 16: 967-974
    CrossrefPubMedGoogle Scholar
  • 23 Hanley SP, Bevan J, Cockbill S, Heptinstall S. The effect of low dose aspirin on human venous prostacyclin production and platelet thromboxane synthesis. Thromb Haemostas 1981; 46: 51 (Abstr)
    PubMedGoogle Scholar
  • 24 FitzGerald GA, Brasch AR, Maas R, Oates JA, Roberts LJ. Endogenous production of prostacyclin and thromboxane during chronic aspirin therapy. Circulaion 1981; 64: 4-55
    PubMedGoogle Scholar
  • 25 Viinikka L, Ylikorkala O. Effects of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Br J Pharmacol 1981; 72: 299-303
    CrossrefPubMedGoogle Scholar
  • 26 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319
    CrossrefPubMedGoogle Scholar
  • 27 Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibiton by low doses of aspirin. J Clin Invest 1979; 63: 532-535
    CrossrefPubMedGoogle Scholar
  • 28 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
    CrossrefPubMedGoogle Scholar
  • 29 Huijgens PC, van den Berg CA M, van der Meer C, Imandt LM F M, Langenhuisen MM A C. Dosage of acetylsalicylic acid for inhibition of platelet function. Scand J Haematol 1980; 25: 76-80
    PubMedGoogle Scholar
  • 30 Czervionke RL, Smith JB, Fry GL, Hoak JC, Haycraft DL. Inhibition of prostacyclin by treatment of endothelium with aspirin: Correlation with platelet adherence. J Clin Invest 1979; 63: 1089-1092
    CrossrefPubMedGoogle Scholar
  • 31 Longmore DB, Hoyle PM, Gregory A, Graeme BennetJ, Smith MA, Osivand T. Prostacyclin administration during cardiopulmonary bypass in man. Lancet 1981; 1: 800-804
    PubMedGoogle Scholar
  • 32 Dewanjee MK, Vogel SR, Peterson KA, Kaye MP. Quantitation of platelet lysis, platelet consumption on oxygenator and stabilization of platelet membrane with prostacyclin and ibuprofen during cardiopulmonary bypass surgery in dogs. Thromb Haemostas 1981; 46: 263 (Abstr)
    PubMedGoogle Scholar
  • 33 Matthias FR, Ditter H, Heinrich D, Simon J, Sohngen D, Schleussner E, Walter P. Effect of prostacyclin (PGI2) on the release of ß- thromboglobulin (ß-TG) and platelet factor 4 (PF4) during extracorporeal circulation. Thromb Haemostas 1981; 46: 316 (Abstr)
    PubMedGoogle Scholar
  • 34 Zimmermann R, Peter J, Jung G, Horsch A, Möri H, Harenberg J. Antithrombotic and opposite effects of drugs influencing the prostaglandin system. Thromb Haemostas 1981; 46: 179 (Abstr)
    PubMedGoogle Scholar
  • 35 Brox J, Østerud B. The effect of prostacyclin (PGI2) on the procoagulant activity of human platelets. Thromb Haemostas 1981; 46: 271 (Abstr)
    PubMedGoogle Scholar
  • 36 Bertele V, Tomasiak M, Falanga A, Cerletti C, de Gaetano G. Aspirin inhibits platelet aggregation but not because it prevents thromboxane synthesis. Lancet 1982; 2: 775
    PubMedGoogle Scholar
  • 37 Dale J, Myhre E, Rootwelt K. Effects of dipyridamole and acetylsalicylic acid on platelet functions in patients with aortic ball-valve prostheses. Am Heart J 1975; 89: 613-618
    CrossrefPubMedGoogle Scholar